One of the most talked about names in the USA in the last days was Moncef Slaoui. When Muslim Doctor Moncef Slaoui was included in the vaccine development team, which all Americans had hoped for, he was one of the most talked about names in the country's agenda. So, who is Moncef Slaoui, where is it, what is his specialty? Here is the biography of Moncef Slaoui:
Moncef Slaoui, 61, was born in 1959 in Casablanca, Morocco. He completed his primary, secondary and high school education in Casablanca. Later he received higher education in Europe.
"World-renowned, private-sector immunologist who has helped 14 new vaccine discoveries in 10 years of work in the private sector. One of the world's most respected men in the formulation of vaccines," said US President Trump for Slaoui. had used the expression.
Saying that he is proud to join the vaccine development team within the scope of "Warp Speed", Saloui said, "When I examine the vaccine experiments against coronavirus, I have increased confidence that we may have distributed hundreds of millions of vaccines by the end of 2020." had used the expression.
Saloui, who is stated to have lost his sister from a fever sickness, who was born in 1959 in the Agadir region of Morocco. Slaoui, after finishing high school in Casablanca, studied in biological sciences in Belgium.
He continues his studies at Harvard Medical School and Tufts University Faculty of Medicine and has more than 100 international articles, and is also a board member of the organization called "AIDS Vaccine Initiative".
Slaoui taught as an immunology professor at the University of Mons in Belgium. He also authored more than 100 research papers. In July 2013, he wrote an op-ed in the Huffington Post titled "It’s Time to Further Incentivize Medical Innovation", in which he outlined three recommendations to improve the effectiveness of the pharmaceutical industry. In April 2013, he co-wrote a paper with several other GSK heads that introduced the term "electroceutical" to broadly encompass medical devices that use electrical, mechanical, or light stimulation to affect electrical signaling in relevant tissue types.
Slaoui spent thirty years working at pharmaceutical giant GlaxoSmithKline (GSK). In 2006, he was appointed head of research and development, succeeding Tachi Yamada. In 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost $100 million; it ceased operations in August 2017. In 2008, Slaoui led the $720 million acquisition of Sirtris Pharmaceuticals, which folded in 2013. In 2012, he oversaw GSK's purchase of Human Genome Sciences for over $3 billion. During his time in GSK, Slaoui oversaw the development of numerous vaccines, including Cervarix to prevent cervical cancer, Rotarix to prevent gastroenteritis in children, and an Ebola vaccine. He also spent 27 years researching on a malaria vaccine, Mosquirix, that was approved by the European Medicines Agency in 2015 and touted as the first in the world. In 2016, Fortune listed Slaoui as one of "The World's 50 Greatest Leaders", crediting him with "attacking the under-researched diseases that plague the developing world." In September 2017, after leaving GSK, Slaoui joined European venture capital firm Medicxi.
On May 15, President Donald Trump officially announced Operation Warp Speed, a project to develop and deliver 300 million doses of a vaccine for the coronavirus disease 2019 by January 2021. Operation Warp Speed was managed by White House senior adviser Jared Kushner with the support of the United States Department of Defense and the United States Department of Health and Human Services. Slaoui, who called the 12-to-18 month time frame "very aggressive" but "achievable", was named as the chief adviser of the project, working alongside chief operating officer and four-star general Gustave F. Perna. Other candidates for Slaoui's position reportedly included Elias Zerhouni and Arthur Levinson. Secretary of Health and Human Services Alex Azar praised Slaoui as "arguably the world’s most experienced and successful vaccine developer".
To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus. Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation.